drugset / Trial / NCT00535951

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

NCT00535951

Phase 1 Completed 18 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural mesothelioma patients

Timeline

Start
2007-11
Primary completion
2009-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule Oral